09639400600

Saturday To Thursday 9 am To 6 pm
butwwbuttw

Diabetes Medications

  Refine Search
Medicine by Generic
  Featured
  Specials
  Featured


Adlina 5 mg Tab

Adlina 5 mg Tab

Adlina 5 mg Tab..

Tk.20.00/=

  0 отзывов

Comet 500 Tablet

Comet 500 Tablet

Comet 500 Tablet..

Tk.4.02/=

  0 отзывов

Comet 850 Tablet

Comet 850 Tablet

Comet 850 Tablet..

Tk.6.02/=

  0 отзывов

Comet XR 1 gm

Comet XR 1 gm

..

Tk.9.03/=

  0 отзывов

Comet XR 500

Comet XR 500

..

Tk.6.02/=

  0 отзывов

Comprid 80 mg Tablet

Comprid 80 mg Tablet

Comprid 80 mg Tab..

Tk.7.02/=

  0 отзывов

Comprid XR 30

Comprid XR 30

Comprid XR 30 Tab..

Tk.6.04/=

  0 отзывов

Comprid XR 60 Tablet

Comprid XR 60 Tablet

Comprid XR 60 Tablet..

Tk.11.03/=

  0 отзывов

Consucon 60 mg MR Tab

Consucon 60 mg MR Tab

Consucon 60 mg MR TabDescriptionConsucon (Gliclazide) is a second generation sulfonylurea drug that has hypoglycaemic and potentially useful haemobiological properties. It stimulates the release of insulin from pancreatic beta-cells by facilitating Ca+2 transport across the beta-cell membranes and decreases hepatic glucose output.IndicationsConsucon and Consucon MR is indicated for the treatment of type 2 diabetes mellitus.Dosage & AdministrationConsucon: The usual initial dose is 40 to 80 mg daily. The dose can be increased upto 320 mg daily in divided doses when needed. The drug should be taken before meal.Consucon MR: The usual daily dosage is 1 to 4 tablets per day as a single dose. It is recommended that the drug should be taken at breakfast time. It is preferable to take this drug before breakfast in order to avoid or to minimize the possible onset of digestive disorders.Side EffectsThere may be hypoglycaemia in concurrent conditions such as hepatic and renal disease, malnutrition, alcohol intoxication. Sometimes headache, gastrointestinal upsets, nausea, dizziness, skin reactions including rash, pruritus, erythema may occur.PrecautionsGliclazide should be used carefully in patients with hepatic impairment. If there is definite hepatic disease then gliclazide should not be used. Consucon (Gliclazide) can be used safely in patients with renal insufficiency as it is extensively metabolized. Consucon has less sudden hypoglycaemic episode than other sulfonylurea group of drugs.Use in Pregnancy & LactationPregnant Women: Gliclazide should not be used in pregnant women although animal studies of Gliclazide have not shown any teratogenic effect.Nursing Mothers: This drug is contraindicated when breast feeding.Over DoseIn accidental overdose, at first gastric lavage should be done and at the same time the hypoglycaemia should be corrected. In severe cases I/V infusion of 5% glucose should be started immediately with frequent monitoring of blood glucose and potassium level...

Tk.11.00/=

  0 отзывов

Consucon 80 mg Tablet

Consucon 80 mg Tablet

Consucon 80 mg TabletDescriptionConsucon (Gliclazide) is a second generation sulfonylurea drug that has hypoglycaemic and potentially useful haemobiological properties. It stimulates the release of insulin from pancreatic beta-cells by facilitating Ca+2 transport across the beta-cell membranes and decreases hepatic glucose output.IndicationsConsucon and Consucon MR is indicated for the treatment of type 2 diabetes mellitus.Dosage & AdministrationConsucon: The usual initial dose is 40 to 80 mg daily. The dose can be increased upto 320 mg daily in divided doses when needed. The drug should be taken before meal.Consucon MR: The usual daily dosage is 1 to 4 tablets per day as a single dose. It is recommended that the drug should be taken at breakfast time. It is preferable to take this drug before breakfast in order to avoid or to minimize the possible onset of digestive disorders.Side EffectsThere may be hypoglycaemia in concurrent conditions such as hepatic and renal disease, malnutrition, alcohol intoxication. Sometimes headache, gastrointestinal upsets, nausea, dizziness, skin reactions including rash, pruritus, erythema may occur.PrecautionsGliclazide should be used carefully in patients with hepatic impairment. If there is definite hepatic disease then gliclazide should not be used. Consucon (Gliclazide) can be used safely in patients with renal insufficiency as it is extensively metabolized. Consucon has less sudden hypoglycaemic episode than other sulfonylurea group of drugs.Use in Pregnancy & LactationPregnant Women: Gliclazide should not be used in pregnant women although animal studies of Gliclazide have not shown any teratogenic effect.Nursing Mothers: This drug is contraindicated when breast feeding.Over DoseIn accidental overdose, at first gastric lavage should be done and at the same time the hypoglycaemia should be corrected. In severe cases I/V infusion of 5% glucose should be started immediately with frequent monitoring of blood glucose and potassium level...

Tk.7.00/=

  0 отзывов

Consucon MR 30 mg Tab

Consucon MR 30 mg Tab

Consucon MR 30 mg TabDescriptionConsucon (Gliclazide) is a second generation sulfonylurea drug that has hypoglycaemic and potentially useful haemobiological properties. It stimulates the release of insulin from pancreatic beta-cells by facilitating Ca+2 transport across the beta-cell membranes and decreases hepatic glucose output.IndicationsConsucon and Consucon MR is indicated for the treatment of type 2 diabetes mellitus.Dosage & AdministrationConsucon: The usual initial dose is 40 to 80 mg daily. The dose can be increased upto 320 mg daily in divided doses when needed. The drug should be taken before meal.Consucon MR: The usual daily dosage is 1 to 4 tablets per day as a single dose. It is recommended that the drug should be taken at breakfast time. It is preferable to take this drug before breakfast in order to avoid or to minimize the possible onset of digestive disorders.Side EffectsThere may be hypoglycaemia in concurrent conditions such as hepatic and renal disease, malnutrition, alcohol intoxication. Sometimes headache, gastrointestinal upsets, nausea, dizziness, skin reactions including rash, pruritus, erythema may occur.PrecautionsGliclazide should be used carefully in patients with hepatic impairment. If there is definite hepatic disease then gliclazide should not be used. Consucon (Gliclazide) can be used safely in patients with renal insufficiency as it is extensively metabolized. Consucon has less sudden hypoglycaemic episode than other sulfonylurea group of drugs.Use in Pregnancy & LactationPregnant Women: Gliclazide should not be used in pregnant women although animal studies of Gliclazide have not shown any teratogenic effect.Nursing Mothers: This drug is contraindicated when breast feeding.Over DoseIn accidental overdose, at first gastric lavage should be done and at the same time the hypoglycaemia should be corrected. In severe cases I/V infusion of 5% glucose should be started immediately with frequent monitoring of blood glucose and potassium level...

Tk.6.00/=

  0 отзывов

Daomin XR 500 Tab

Daomin XR 500 Tab

Daomin XR 500 Tab..

Tk.6.00/=

  0 отзывов

DIAMICRON MR 30 mg Tab

DIAMICRON MR 30 mg Tab

DIAMICRON MR 30 mg Tab..

Tk.12.00/=

  0 отзывов

DIAMICRON MR 60 mg Tab

DIAMICRON MR 60 mg Tab

DIAMICRON MR 60 mg Tab..

Tk.18.50/=

  0 отзывов

Diapro 30 MR

Diapro 30 MR

What Diapro® MR is and what it is used for?Gliclazide is a second generation sulfonylurea that has hypoglycemic and potentially useful hemobiological properties. It stimulates the influx of calcium ions into pancreatic beta cells and as a result increases insulin secretion. Moreover, in vivo studies have demonstrated changes in thrombin-induced platelet aggregation in NIDDM patients treated with gliclazide. Non-insulin dependent diabetes mellitus (type-II) when dietary modification has failed.Before you take Diapro® MRHigh Risk GroupsNeonates : The drug is not used in neonatesNursing mothers : The drug should not be used by breast-feeding mothers.Children : Gliclazide is contraindicated in childrenPregnant women : Gliclazide, as other sulfonylurea, is contraindicated for use in pregnant women. No teratological changes have been shown in animals or human, but diabetes can be controlled more tightly in pregnancy by insulin than by oral hypoglycemic agents.Elderly : All sulfonylureas should be used with caution in the elderly because of the greater likelihood of their missing meals and the more severe outcome of significant hypoglycemia.Concurrent disease : Definite hepatic disease should contraindicate the use of Gliclazide, since it is almost completely metabolized in the liver. Renal disease does not appear significantly to alter the pharmacokinetics, although it may be wise to limit the maximum dose when the serum creatinine starts to rise.Drug InteractionsPotentially hazardous interactions - These may be divided into those which will tend to increase the hypoglycemic effect and those tending to oppose it. In the first category come drugs which displace the sulfonylurea from protein binding, such as aspirin, non-steroidal anti-inflammatory drugs, phenylbutazone, clofibrate, sulfonamides and coumarin anticoagulants, or which inhibit, hepatic microsomal enzymes, for example cimetidine, sulfonamides, imidazole antifungal agents and the monoamine oxidase inhibitors (MAOI), which may increase the hypoglycemic effect of Gliclazide. Any effects, which result from protein-binding displacement, are transient, lasting from 12-24 hrs. Regular concomitant doses of these agents together with a constant dose of Gliclazide would not cause problems.The hypoglycemic action of sulfonylureas may be opposed by the induction of hepatic enzymes, which metabolize the drug causing lower plasma concentrations and less hypoglycemic effect. Common inducers include rifampicin, barbiturates, phenytoin and alcohol, or by drugs that inhibit the release or action of insulin, e.g. thiazide diuretics, dizoxide, glucocorticoids, estrogens or sympathomimetic drugs. Early symptoms of hypoglycemia such as tremor, sweating and tachycardia may be masked by beta-adrenoreceptor blocking drugs, such as propranolol allowing severe hypoglycemic episodes without preceding warning symptoms. If beta-adrenoreceptor blocking drugs are required the moreselective types, such as metoprolol or atenolol, are preferred in the diabetic patient.How to take Diapro® MRInitially 40-80 mg daily, adjusted according to response; up to 160 mg as a single dose, with breakfast; higher doses divided; maximum 320 mg daily. Switching from Gliclazide 80 mg tablets to Gliclazide 30 mg modified release tablets. 1 tablet of Gliclazide 80 mg is comparable to 1 tablet of Gliclazide 30 mg modified release tablet. Consequently the switch can be performed provided a careful blood monitoring.Possible side effectsPotentially life-threatening effects - All hypoglycemic agents have the potential to cause severe hypoglycemia and may cause severe brain damage or death. Gliclazide used in standard dose is less likely than glyburide to cause hypoglycemia. Hypoglycemia may be favored by concurrent conditions such as hepatic and renal disease, malnutrition, anorexia, senility, alcohol intoxication or adrenal and pituitary insufficiency.Severe or irreversible adverse effects - Approximately 2% of patients have been withdrawn from therapy because of adverse reactions, namely hypoglycemia (overdose effect), gastrointestinal disturbances and dermatological reactions.Symptomatic adverse effects - Side effects of Gliclazide treatment are similar to those of other sulfonylureas. Headache, gastrointestinal upsets, nausea and dizziness have been reported and skin reactions, including rash, pruritus, erythema and bullous eruptions may occur. Abnormalities of liver function are not uncommon.How to store Diapro® MRKeep in a cool & dry place. Protect from light. Keep out of the reach of children...

Tk.7.00/=

  0 отзывов

Diapro 60 MR

Diapro 60 MR

Diapro 60 MRWhat Diapro® 60 MR is and what it is used for?Diapro® 60 MR is a preparation of Gliclazide which is a second generation sulphonylurea used as a Non-insulin dependent diabetes mellitus (type-II) when dietary modification has failed.Before you take Diapro® 60 MRDo not take the medicine and talk to your doctor ifHypoglycemia (overdose effect), gastrointestinal disturbances and dermatological reactions occur.Take special care withAll sulfonylureas should be used with caution in the elderly because of the greater likelihood of their missing meals and the more severe outcome of significant hypoglycemia.Early symptoms of hypoglycemia such as tremor, sweating and tachycardia may be masked by beta-adrenoreceptor blocking drugs, such as propranolol allowing severe hypoglycemic episodes without preceding warning symptoms.ContraindicationDiapro® 60 MR is contraindicated in patients with definite hepatic disease. Renal disease does not appear significantly to alter the pharmacokinetics, although it may be wise to limit the maximum dose when the serum creatinine starts to rise.Tell your doctor if you are taking other medicinesDrug interactions occur with rifampicin, barbiturates, phenytoin, and alcohol, or drugs that inhibit release of insulin like thiazide diuretics, dioxides, glucocorticoids, estrogens or sympathomimetic drugs.Pregnancy and breast-feedingDiapro® 60 MR should not be used in nursing mothers. It is contraindicated in children and pregnant women.How to take Diapro® 60 MR?Dosage and AdministrationsInitially 40-80 mg daily, adjusted according to response; up to 160 mg as a single dose, with breakfast; higher doses divided; maximum 320 mg daily.Switching from Gliclazide 80 mg tablets to Gliclazide 30 mg & 60 mg modified release tablets:1 tablet of Gliclazide 80 mg is comparable to 1 tablet of Gliclazide 30 mg modified release tablet. Consequently the switch can be performed provided a careful blood monitoring.One Gliclazide 60 mg modified release tablet is equivalent to two Gliclazide 30 mg modified release tablets. Gliclazide 60 mg modified release tablets can be used to replace other oral antidiabetic agents.Possible side effectsPotentially life-threatening effects - All hypoglycemic agents have the potential to cause severe hypoglycemia and may cause severe brain damage or death. Gliclazide used in standard dose is less likely than glyburide to cause hypoglycemia. Hypoglycemia may be favored by concurrent conditions such as hepatic and renal disease, malnutrition, anorexia, senility, alcohol intoxication or adrenal and pituitary insufficiency.Severe or irreversible adverse effects - Approximately 2% of patients have been withdrawn from therapy because of adverse reactions, namely hypoglycemia (overdose effect), gastrointestinal disturbances and dermatological reactions.Symptomatic adverse effects - Side effects of Gliclazide treatment are similar to those of other sulfonylureas. Headache, gastrointestinal upsets, nausea and dizziness have been reported and skin reactions, including rash, pruritus, erythema and bullous eruptions may occur. Abnormalities of liver function are not uncommon.Tell your doctor if any of the side effects gets serious or lasts longer than a few days, or if you notice any side effects not listed in this leafletHow to store Diapro® 60 MR?Keep in a cool & dry place. Protect from light. Keep out of the reach of children.Do not store above 25°C (room temperature). Do not freeze...

Tk.12.01/=

  0 отзывов

Diapro tab

Diapro tab

Diapro tab1. What Diapro® is and what it is used for?Gliclazide is a second generation sulfonylurea that has hypoglycemic and potentially useful hemobiological properties. It stimulates the influx of calcium ions into pancreatic beta cells and as a result, increases insulin secretion. Moreover, in vivo studies have demonstrated changes in thrombin-induced platelet aggregation in NIDDM patients treated with gliclazide. Non-insulin dependent diabetes mellitus (type-II) when dietary modification has failed.2. Before you take Diapro®High Risk GroupsNeonates - The drug is not used in neonatesNursing mothers - The drug should not be used by breast-feeding mothers.Children - Gliclazide is contraindicated in childrenPregnant women - Gliclazide, as other sulfonylurea, is contraindicated for use in pregnant women. No teratological changes have been shown in animals or human, but diabetes can be controlled more tightly in pregnancy by insulin than by oral hypoglycemic agents.Elderly - All sulfonylureas should be used with caution in the elderly because of the greater likelihood of their missing meals and the more severe outcome of significant hypoglycemia.Concurrent diseaseDefinite hepatic disease should contraindicate the use of Gliclazide, since it is almost completely metabolized in the liver. Renal disease does not appear significantly to alter the pharmacokinetics, although it may be wise to limit the maximum dose when the serum creatinine starts to rise.3. How to take Diapro®?Initially 40-80 mg daily, adjusted according to response; up to 160 mg as a single dose, with breakfast; higher doses divided; maximum 320 mg daily.4. Possible side effectsPotentially life-threatening effects – All hypoglycemic agents have the potential to cause severe hypoglycemia and may cause severe brain damage or death. Gliclazide used in standard dose is less likely than glyburide to cause hypoglycemia. Hypoglycemia may be favored by concurrent conditions such as hepatic and renal disease, malnutrition, anorexia, senility, alcohol intoxication or adrenal and pituitary insufficiency.Severe or irreversible adverse effects - Approximately 2% of patients have been withdrawn from therapy because of adverse reactions, namely hypoglycemia (overdose effect), gastrointestinal disturbances and dermatological reactions.Symptomatic adverse effects - Side effects of Gliclazide treatment are similar to those of other sulfonylureas. Headache, gastrointestinal upsets, nausea and dizziness have been reported and skin reactions, including rash, pruritus, erythema and bullous eruptions may occur. Abnormalities of liver function are not uncommon.5. How to store Diapro®?Store below 25° C...

Tk.7.00/=

  0 отзывов

Dieta 1mg Tab

Dieta 1mg Tab

Dieta 1 Tab..

Tk.5.00/=

  0 отзывов

Dieta 2 Tab

Dieta 2 Tab

Dieta 2 Tab..

Tk.9.00/=

  0 отзывов

Dimerol 80 Tab

Dimerol 80 Tab

Dimerol Tab..

Tk.8.00/=

  0 отзывов

Etform 850 tablet

Etform 850 tablet

Etform 850 tablet..

Tk.5.50/=

  0 отзывов

Galet  50mg Tab

Galet 50mg Tab

Galet Tab..

Tk.15.00/=

  0 отзывов

Galet-M 50/850

Galet-M 50/850

galet-m 50/850..

Tk.22.00/=

  0 отзывов

Galet-M 500 mg

Galet-M 500 mg

..

Tk.18.00/=

  0 отзывов

Galvus 50mg Tab

Galvus 50mg Tab

..

Tk.31.50/=

  0 отзывов

Galvus Met 50 mg/850 mg Tab

Galvus Met 50 mg/850 mg Tab

..

Tk.33.00/=

  0 отзывов

Galvus Met 50/1000

Galvus Met 50/1000

..

Tk.40.00/=

  0 отзывов

Gliclid Tab

Gliclid Tab

Gliclid..

Tk.7.02/=

  0 отзывов

Glipita 100 tablet

Glipita 100 tablet

What is Glipita?Glipita is the preparation of Sitagliptin. Sitagliptin is a new oral agent approved by the USFDA to treat type 2 diabetes with diet & exercise. It belongs to a new class of antihyperglycemic, Dipeptidyl Dipeptidase-4 (DPP-4) inhibitors. This unique class of orally active agent targets the underlying pathophysiologic processes of type 2 diabetic patients and provides an excellent alternative to the traditional agents.How Glipita works in our body?Normally, when glucose appears in blood after meal, Incretin hormones (GLP-1 & GIP) are secreted from gut to stimulate pancreatic β cell for insulin secretion and to act on α cell for glucagon inhibition. Dipeptidyl Peptidase 4 (DPP-4), an enzyme present in plasma, inactivates GLP-1 & GIP to stop insulin secretion from pancreatic β cell and to increase uninterrupted glucagon secretion from pancreatic α cell. Sitagliptin inhibits plasma DPP-4 activity (i.e. inactivation of GLP & GIP) and thus, increases circulating levels of active GLP-1 and GIP by two-to-threefold. This in turn, increases insulin release from pancreatic β cell and decreases glucagon levels from pancreatic α cell in the circulation in a glucose-dependent manner. Therefore, Sitagliptin is the only oral drug that involves both pancreatic α & β cell in a complimentary mode of action and thus ensures effective glycemic control in type 2 diabetes.What is the indications of Glipita?Monotherapy- GLIPITA is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Combination with Metformin- GLIPITA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with Metformin as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with a Sulfonylurea- GLIPITA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with a sulfonylurea when treatment with the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with a Thiazolidinediones- GLIPITA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with a thiazolidinedione when treatment with the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with Metformin and a Sulfonylurea- GLIPITA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with Metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise, does not provide adequate glycemic control.What is the dosage guideline for Glipita?The recommended dose of SITAGLIPTIN is 100 mg once daily as monotherapy or as combination therapy with Metformin, a sulfonylurea, a thiazolidinedione, or Metformin plus a sulfonylurea. SITAGLIPTIN can be taken with or without food. Patients with Renal Insufficiency- For patients with mild renal insufficiency (creatinine clearance [CrCl] ≥50 mL/min, approximately corresponding to serum creatinine levels of ≤1.7 mg/dL in men and ≤1.5 mg/dL in women), no dosage adjustment for SITAGLIPTIN is required. For patients with moderate renal insufficiency (CrCl ≥30 to <50 mL/min, approximately corresponding to serum creatinine levels of >1.7 to ≤3.0 mg/dL in men and >1.5 to ≤2.5 mg/dL in women), the dose of SITAGLIPTIN is 50 mg once daily. For patients with severe renal insufficiency (CrCl <30 mL/min, approximately corresponding to serum creatinine levels of >3.0 mg/dL in men and >2.5 mg/dL in women) or with end -stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of SITAGLIPTIN is 25 mg once daily. SITAGLIPTIN may be administered without regard to the timing of hemodialysis. Concomitant Use with a Sulfonylurea- When SITAGLIPTIN is used in combination with a sulfonylurea, a lower dose of sulfonylurea may be required to reduce the risk of hypoglycemia. Patients with Hepatic Insufficiency- No dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency. SITAGLIPTIN has not been studied in patients with severe hepatic insufficiency. Elderly- No dosage adjustment is necessary for elderly patients. Pediatric population- There is no data on the use of SITAGLIPTIN in patients younger than 18 years of age and therefore not recommended.Is there any dosage guideline for special population like renal insufficient patient with type 2 diabetes?Dosage adjustments in patients with moderate, severe, or end-stage renal disease (ESRD)50 mg once daily Moderate25 mg once daily Severe and ESRDCrCl ≥30 to <50 mL/min ˜Serum Cr levels (mg/dL)CrCl <30 mL/min ˜Serum Cr levels (mg/dL)Men: >1.7 – ≤3.0 Women: >1.5 – ≤2.5Men: >3.0 Women: >2.5 or on dialysisWhat are the precautions should I follow?SITAGLIPTIN should not be used in patients with type 1 diabetes or for the trea..

Tk.25.00/=

  0 отзывов

Glipita 50 tablet

Glipita 50 tablet

Glipita 50 tabletWhat is Glipita?Glipita is the preparation of Sitagliptin. Sitagliptin is a new oral agent approved by the USFDA to treat type 2 diabetes with diet & exercise. It belongs to a new class of antihyperglycemic, Dipeptidyl Dipeptidase-4 (DPP-4) inhibitors. This unique class of orally active agent targets the underlying pathophysiologic processes of type 2 diabetic patients and provides an excellent alternative to the traditional agents.How Glipita works in our body?Normally, when glucose appears in blood after meal, Incretin hormones (GLP-1 & GIP) are secreted from gut to stimulate pancreatic β cell for insulin secretion and to act on α cell for glucagon inhibition. Dipeptidyl Peptidase 4 (DPP-4), an enzyme present in plasma, inactivates GLP-1 & GIP to stop insulin secretion from pancreatic β cell and to increase uninterrupted glucagon secretion from pancreatic α cell. Sitagliptin inhibits plasma DPP-4 activity (i.e. inactivation of GLP & GIP) and thus, increases circulating levels of active GLP-1 and GIP by two-to-threefold. This in turn, increases insulin release from pancreatic β cell and decreases glucagon levels from pancreatic α cell in the circulation in a glucose-dependent manner. Therefore, Sitagliptin is the only oral drug that involves both pancreatic α & β cell in a complimentary mode of action and thus ensures effective glycemic control in type 2 diabetes.What is the indications of Glipita?Monotherapy- GLIPITA is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus. Combination with Metformin- GLIPITA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with Metformin as initial therapy or when the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with a Sulfonylurea- GLIPITA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with a sulfonylurea when treatment with the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with a Thiazolidinediones- GLIPITA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with a thiazolidinedione when treatment with the single agent alone, with diet and exercise, does not provide adequate glycemic control. Combination with Metformin and a Sulfonylurea- GLIPITA is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with Metformin and a sulfonylurea when dual therapy with these agents, with diet and exercise, does not provide adequate glycemic control.What is the dosage guideline for Glipita?The recommended dose of SITAGLIPTIN is 100 mg once daily as monotherapy or as combination therapy with Metformin, a sulfonylurea, a thiazolidinedione, or Metformin plus a sulfonylurea. SITAGLIPTIN can be taken with or without food. Patients with Renal Insufficiency- For patients with mild renal insufficiency (creatinine clearance [CrCl] ≥50 mL/min, approximately corresponding to serum creatinine levels of ≤1.7 mg/dL in men and ≤1.5 mg/dL in women), no dosage adjustment for SITAGLIPTIN is required. For patients with moderate renal insufficiency (CrCl ≥30 to <50 mL/min, approximately corresponding to serum creatinine levels of >1.7 to ≤3.0 mg/dL in men and >1.5 to ≤2.5 mg/dL in women), the dose of SITAGLIPTIN is 50 mg once daily. For patients with severe renal insufficiency (CrCl <30 mL/min, approximately corresponding to serum creatinine levels of >3.0 mg/dL in men and >2.5 mg/dL in women) or with end -stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis, the dose of SITAGLIPTIN is 25 mg once daily. SITAGLIPTIN may be administered without regard to the timing of hemodialysis. Concomitant Use with a Sulfonylurea- When SITAGLIPTIN is used in combination with a sulfonylurea, a lower dose of sulfonylurea may be required to reduce the risk of hypoglycemia. Patients with Hepatic Insufficiency- No dosage adjustment is necessary for patients with mild to moderate hepatic insufficiency. SITAGLIPTIN has not been studied in patients with severe hepatic insufficiency. Elderly- No dosage adjustment is necessary for elderly patients. Pediatric population- There is no data on the use of SITAGLIPTIN in patients younger than 18 years of age and therefore not recommended.Is there any dosage guideline for special population like renal insufficient patient with type 2 diabetes?Dosage adjustments in patients with moderate, severe, or end-stage renal disease (ESRD)50 mg once daily Moderate25 mg once daily Severe and ESRDCrCl ≥30 to <50 mL/min ˜Serum Cr levels (mg/dL)CrCl <30 mL/min ˜Serum Cr levels (mg/dL)Men: >1.7 – ≤3.0 Women: >1.5 – ≤2.5Men: >3.0 Women: >2.5 or on dialysisWhat are the precautions should I follow?SITAGLIPTIN should not be used in patients with type 1 diabete..

Tk.13.01/=

  0 отзывов

Glipita M 50/1000 tablet

Glipita M 50/1000 tablet

Glipita M 50/1000 tabletWhat is Glipita-M?Glipita-M is the preparation of sitagliptin and metformin. Sitagliptin phosphate, a dipeptidyl peptidase 4(DPP-4) inhibitor and metformin HCI, a member of the biguanide class. Glipita-M is indicated as an adjunct to diet and exercise to treat Type 2 diabetes where metfromin is not enough to improve glycemic control. FDA Approves Glipita-M For Type 2 Diabetes, Offering Powerful Glucose Control Of A DPP-4 Inhibitor And Metformin in a Single Tablet.How Glipita works in our body?Glipita-M (sitagliptin phosphate/metformin HCI) combines 2 antihyperglycemic agents with complementary mechanism of action to improve glycemic control in patients with type 2 diabetes. Sitagliptin increases the levels of 2 known active incretin hormones, glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic β-cells. GLP-1 also lowers glucagon secretion from pancreatic α-cells, leading to reduced hepatic glucose production. Metformin improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. It decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.What is the indications of Glipita-M?As initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. As adjunct to diet & exercise to improve glycemic control in type 2 DM inadequately controlled on metformin or sitagliptin alone, or combination sitagliptin & metformin, or triple combination sitagliptin, metformin or a sulfonylurea.What are Dosage of Glipita-M?The dosage of Glipita-M should be individualized on the basis of the patient’s current regimen, effectiveness and tolerabilty while not excceding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. Initial combination therapy or maintenance of combination therapy should be individualized and left to the discretion of the health care provider . Glipita-M shoul generally be given twice daily with meals , with gradual dose escalation , to reducethe gasterointestinal side effect due to metformin. The recommended starting dose not currently treated with metformin is 50 mg sitagliptin/500 mg metformin hydrochloride twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin .The starting dose in patient already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg toatal daily dose )and the dose of metformin already being taken. For patients taking 850 mg twice daily the recommended starting dose of Glipita-M is 50 mg sitagliptin/1000 mg metformin hydrochloride twice daily.Patients treated with an insulin secrtagauge or insulin co-administration of Glipita-M with an insulin secrtagauge (e.g. sulfonylurea) or insulin may require lower dose of insulin secretagauge or insulin to reduce the risk of hypoglycemia .No studies have been performed specifically examining the safety and efficacy of Glipita-M in patients previously treated with other oral antihyperglycemic agents and switched to Glipita-M.What is the Use of Glipita-M in Specific Populations:Pregnancy: Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women with Sitagliptin/Metformin HCl combination or its individual components; therefore, the safety of Sitagliptin/Metformin HCl combination in pregnant women is not known. Nursing Mothers: No studies in lactating animals have been conducted with the combined components of Sitagliptin/Metformin HCl combination. Pediatric Use: Safety and effectiveness of Sitagliptin/Metformin HCl combination in pediatric patients under 18 years have not been established.Geriatric Use: Because sitagliptin and metformin are substantially excreted by the kidney, and because aging can be associated with reduced renal function, Sitagliptin/Metformin HCl combination should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function.Selected Important Risk Information:Lactic acidosis is a rare but serious complication that can occur because of metformin accumulation. Glipita M is contraindicated in renal disease or renal dysfunction (serum creatinine levels >1.5 mg/dL in males and >1.4 mg/dL in females) or abnormal creatinine clearance.What are the possible adverse reactions of Glipita-M?Diarrhea, nausea, dyspepsia, flatulence, vomiting, headache, hypoglycaemia; abdominal pain, loss of appetite, metallic taste, hypersensitivity reactions...

Tk.16.00/=

  0 отзывов

Glipita M 50/500 tablet

Glipita M 50/500 tablet

What is Glipita-M?Glipita-M is the preparation of sitagliptin and metformin. Sitagliptin phosphate, a dipeptidyl peptidase 4(DPP-4) inhibitor and metformin HCI, a member of the biguanide class. Glipita-M is indicated as an adjunct to diet and exercise to treat Type 2 diabetes where metfromin is not enough to improve glycemic control. FDA Approves Glipita-M For Type 2 Diabetes, Offering Powerful Glucose Control Of A DPP-4 Inhibitor And Metformin in a Single Tablet.How Glipita works in our body?Glipita-M (sitagliptin phosphate/metformin HCI) combines 2 antihyperglycemic agents with complementary mechanism of action to improve glycemic control in patients with type 2 diabetes. Sitagliptin increases the levels of 2 known active incretin hormones, glucagon-like peptide-1(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). When blood glucose concentrations are normal or elevated, GLP-1 and GIP increase insulin synthesis and release from pancreatic β-cells. GLP-1 also lowers glucagon secretion from pancreatic α-cells, leading to reduced hepatic glucose production. Metformin improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. It decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.What is the indications of Glipita-M?As initial therapy in type 2 DM when diet & exercise do not provide adequate glycemic control. As adjunct to diet & exercise to improve glycemic control in type 2 DM inadequately controlled on metformin or sitagliptin alone, or combination sitagliptin & metformin, or triple combination sitagliptin, metformin or a sulfonylurea.What are Dosage of Glipita-M?The dosage of Glipita-M should be individualized on the basis of the patient’s current regimen, effectiveness and tolerabilty while not excceding the maximum recommended daily dose of 100 mg sitagliptin and 2000 mg metformin. Initial combination therapy or maintenance of combination therapy should be individualized and left to the discretion of the health care provider . Glipita-M shoul generally be given twice daily with meals , with gradual dose escalation , to reducethe gasterointestinal side effect due to metformin. The recommended starting dose not currently treated with metformin is 50 mg sitagliptin/500 mg metformin hydrochloride twice daily, with gradual dose escalation recommended to reduce gastrointestinal side effects associated with metformin .The starting dose in patient already treated with metformin should provide sitagliptin dosed as 50 mg twice daily (100 mg toatal daily dose )and the dose of metformin already being taken. For patients taking 850 mg twice daily the recommended starting dose of Glipita-M is 50 mg sitagliptin/1000 mg metformin hydrochloride twice daily.Patients treated with an insulin secrtagauge or insulin co-administration of Glipita-M with an insulin secrtagauge (e.g. sulfonylurea) or insulin may require lower dose of insulin secretagauge or insulin to reduce the risk of hypoglycemia .No studies have been performed specifically examining the safety and efficacy of Glipita-M in patients previously treated with other oral antihyperglycemic agents and switched to Glipita-M.What is the Use of Glipita-M in Specific Populations:Pregnancy: Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women with Sitagliptin/Metformin HCl combination or its individual components; therefore, the safety of Sitagliptin/Metformin HCl combination in pregnant women is not known. Nursing Mothers: No studies in lactating animals have been conducted with the combined components of Sitagliptin/Metformin HCl combination. Pediatric Use: Safety and effectiveness of Sitagliptin/Metformin HCl combination in pediatric patients under 18 years have not been established.Geriatric Use: Because sitagliptin and metformin are substantially excreted by the kidney, and because aging can be associated with reduced renal function, Sitagliptin/Metformin HCl combination should be used with caution as age increases. Care should be taken in dose selection and should be based on careful and regular monitoring of renal function.Selected Important Risk Information:Lactic acidosis is a rare but serious complication that can occur because of metformin accumulation. Glipita M is contraindicated in renal disease or renal dysfunction (serum creatinine levels >1.5 mg/dL in males and >1.4 mg/dL in females) or abnormal creatinine clearance.What are the possible adverse reactions of Glipita-M?Diarrhea, nausea, dyspepsia, flatulence, vomiting, headache, hypoglycaemia; abdominal pain, loss of appetite, metallic taste, hypersensitivity reactions...

Tk.14.00/=

  0 отзывов

Glitin 5 Tab

Glitin 5 Tab

Glitin 5..

Tk.18.00/=

  0 отзывов

Glucodip-MXR 1000

Glucodip-MXR 1000

Glucodip-M XR 1000..

Tk.22.00/=

  0 отзывов

Glucodip-MXR 500

Glucodip-MXR 500

Glucodip-M XR 500..

Tk.20.00/=

  0 отзывов

Glucomet 850mg Tab

Glucomet 850mg Tab

Glucomet 850mg Tab..

Tk.6.00/=

  0 отзывов

Glucozid 80mg Tab

Glucozid 80mg Tab

Glucozid 80mg Tab..

Tk.7.00/=

  0 отзывов

Gluvan 50mg Tab

Gluvan 50mg Tab

Gluvan 50mg Tab..

Tk.20.00/=

  0 отзывов

Incrit 100 mg Tab

Incrit 100 mg Tab

Incrit 100 mg Tab..

Tk.30.00/=

  0 отзывов

Incrit 50 mg Tab

Incrit 50 mg Tab

Incrit 50 mg Tab..

Tk.18.05/=

  0 отзывов

Incrit-M 1000 Tab

Incrit-M 1000 Tab

Incrit-M 1000 Tab..

Tk.22.07/=

  0 отзывов

Incrit-M 500 Tab

Incrit-M 500 Tab

Incrit-M 500 Tab..

Tk.20.06/=

  0 отзывов

Informet LA 500 Tab

Informet LA 500 Tab

Informet LA 500 Tab..

Tk.5.00/=

  0 отзывов

Janmet 1000 Tab

Janmet 1000 Tab

..

Tk.18.04/=

  0 отзывов

Janmet 500

Janmet 500

..

Tk.16.04/=

  0 отзывов

Janvia 100 Tab

Janvia 100 Tab

..

Tk.28.08/=

  0 отзывов

Janvia 50 Tab

Janvia 50 Tab

..

Tk.15.04/=

  0 отзывов

lijenta-5-tab, 1 strip

Lijenta 5 Tab, 1 strip

Lijenta 5 Tab, 1 stripDescription:Lijenta 5 is an inhibitor of DPP-4 , an enzyme that degrades the incretin hormones GLP-1 and GIP. Thus, Linagliptin increases the concentratins of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner and decreasing the secretion of glucangon from pancreatic alpha cells in the circulation.Thus it improves glycemic control in patients with type 2 diabetes mellitus.IndicationLijenta 5 is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults. As monotherapy-in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance or contraindicated due to renal impairment. As combination therapy-in combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control-in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Dosage & Administration5 mg once daily. If added to metformin, the dose of metformin should be maintained and linagliptin administered concomitantly. When used in combination with a sulfonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.Patients with renal impairment: no dose adjustment required. Linagliptin can be taken with or without a meal at any time of the day.ContraindicationHypersensitivity to the active substance or to any of the excipients.PrecautionLinagliptin should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.Side EffectsThere may be hypoglycaemia, nasopharyngitis, cough and pancreatitis in combination with metformin and sulfonylurea.Drug InteractionLinagliptin is a weak competitive and a weak to moderate mechanism-based inhibitor of CYP isozyme CYP3A4, but does not inhibit other CYP isozymes. The risk for clinically meaningful interactions by other medicinal products on linagliptin is low and in clinical studies linagliptin had no clinically relevant effect on the pharmacokinetics of metformin, glyburide, simvastatin, warfarin, digoxin or oral contraceptives.Pregnancy & LactationAvoid use during pregnancy. A risk to the breast-fed child cannot be excluded.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...

Tk.330.00/=

  0 отзывов

lijenta-m-500-tab, 1 strip

Lijenta-M 500 Tab, 1 strip

Lijenta-M 500 Tab, 1 stripDescription:Lijenta-M is a combination of linagliptin and Metformin Hydrochloride with complementary mechanism of action to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha cells in the circulation.Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.IndicationLijenta-M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.Dosage & AdministrationThe dosage of Lijenta-M should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin use.Recommended starting dose: In patients currently not treated with Metformin, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.In patients already treated with Metformin, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.Patients already treated with linagliptin and metformin, individual components may be switched to this combination containing the same doses of each component.ContraindicationAlthough Linagliptin undergoes minimal renal excretion, Metformin is known to be substantially excreted by the kidney. The risk of Metformin accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin.PrecautionIn a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Lijenta-M. Temporarily discontinue Lijenta-M in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.Side EffectsMost common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.Drug InteractionCationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination. P-glycoprotien/CYP3A4 inducer (i.e. rifampin): The efficacy of Lijenta-M may be reduced when administered in combination.Pregnancy & LactationPregnancy category B. There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...

Tk.120.00/=

  0 отзывов

lijenta-m-850-tab, 1 strip

Lijenta-M 850 Tab, 1 strip

Lijenta-M 850 Tab, 1 stripDescription:Lijenta-M is a combination of linagliptin and Metformin Hydrochloride with complementary mechanism of action to improve glycemic control in patients with type 2 diabetes mellitus. Linagliptin is an inhibitor of DPP-4 (dipeptidyl peptidase-4), an enzyme that degrades the incretin hormones GLP-1 (glucagon like peptide-1) and GIP (glucose dependent insulinotropic polypeptide). Thus, Linagliptin increases the concentrations of active incretin hormones, stimulating the release of insulin from pancreatic beta cells in a glucose-dependent manner and decreasing the secretion of glucagon from pancreatic alpha cells in the circulation.Metformin Hydrochloride is a biguanide type oral antihyperglycemic drug used in the management of type 2 diabetes. It lowers both basal and postprandial plasma glucose. Its mechanism of action is different from those of sulfonylureas and it does not produce hypoglycemia. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose and improves insulin sensitivity by an increase in peripheral glucose uptake and utilization.IndicationLijenta-M is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.Dosage & AdministrationThe dosage of Lijenta-M should be individualized on the basis of both effectiveness and tolerability. Maximum recommended dose of 2.5 mg Linagliptin and 1000 mg Metformin Hydrochloride twice daily with meals. Dose escalation should be gradual to reduce the gastrointestinal (GI) side effects associated with Metformin use.Recommended starting dose: In patients currently not treated with Metformin, initiate treatment with 2.5 mg Linagliptin and 500 mg Metformin Hydrochloride twice daily.In patients already treated with Metformin, start with 2.5 mg Linagliptin and the current dose of Metformin Hydrochloride twice daily.Patients already treated with linagliptin and metformin, individual components may be switched to this combination containing the same doses of each component.ContraindicationAlthough Linagliptin undergoes minimal renal excretion, Metformin is known to be substantially excreted by the kidney. The risk of Metformin accumulation and lactic acidosis increases with the degree of renal impairment. Therefore, this combination is contraindicated in patients with renal impairment. It is also contraindicated in acute or chronic metabolic acidosis (diabetic ketoacidosis) and in hypersensitivity to Linagliptin or Metformin.PrecautionIn a patient with lactic acidosis who is taking Metformin, the drug should be discontinued immediately and supportive therapy promptly instituted. There have been postmarketing reports of acute pancreatitis. If pancreatitis is suspected, promptly discontinue Lijenta-M. Temporarily discontinue Lijenta-M in patients undergoing radiologic studies with intravascular administration of iodinated contrast materials or any surgical procedures necessitating restricted intake of food and fluids. Metformin may lower Vitamin B12 levels; so hematologic parameters shoud be monitored annually.Side EffectsMost common side effects are nasopharyngitis and diarrhea. Hypoglycemia is more common in patients treated with this combination and sulfonylureas.Drug InteractionCationic drugs (amiloride, digoxin, morphine, ranitidine, trimethoprim etc.): May reduce metformin elimination. P-glycoprotien/CYP3A4 inducer (i.e. rifampin): The efficacy of Lijenta-M may be reduced when administered in combination.Pregnancy & LactationPregnancy category B. There are no adequate and well-controlled studies in pregnant women with this combination or its individual component; so it should be used during pregnancy only if clearly needed. Caution should also be excercised when it is administered to a lactating mother.Storage ConditionKeep in a dry place away from light and heat. Keep out of the reach of children...

Tk.112.00/=

  0 отзывов

Showing 1 to 50 of 108 (3 Pages)